Holen Sie sich die Stockscreener-App
21.85
2.32%
-0.52
Handel nachbörslich:
21.75
-0.10
-0.46%
Schlusskurs vom Vortag:
$22.37
Offen:
$21.98
24-Stunden-Volumen:
1.38M
Relative Volume:
0.67
Marktkapitalisierung:
$3.69B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
121.39
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
-3.40%
1M Leistung:
+0.23%
6M Leistung:
+46.55%
1J Leistung:
+49.45%
1-Tages-Spanne:
$21.72
$22.20
1-Wochen-Bereich:
$21.72
$22.92
52-Wochen-Spanne:
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Vergleichen Sie ACAD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
21.85 | 3.77B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
(ACAD) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by Burney Co. - MarketBeat
ACADIA Pharmaceuticals board member Daniel Soland resigns - StreetInsider
[8-K] ACADIA PHARMACEUTICALS INC Reports Material Event | ACAD SEC FilingForm 8-K - Stock Titan
How ACADIA Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Understanding ACADIA Pharmaceuticals Inc.’s price movementFed Meeting & Real-Time Buy Signal Alerts - newser.com
Is ACADIA Pharmaceuticals Inc. stock trading near support levelsWeekly Trade Summary & Low Risk Growth Stock Ideas - newser.com
Price momentum metrics for ACADIA Pharmaceuticals Inc. explainedWeekly Risk Report & High Conviction Trade Alerts - newser.com
Will ACADIA Pharmaceuticals Inc. stock split again soonJuly 2025 Volume & Daily Stock Trend Watchlist - newser.com
Why ACADIA Pharmaceuticals Inc. stock remains undervaluedMarket Trend Summary & High Conviction Buy Zone Alerts - newser.com
Is ACADIA Pharmaceuticals Inc. stock a top momentum playJuly 2025 Weekly Recap & Fast Gain Stock Trading Tips - newser.com
ACADIA Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Reactions & AI Powered Market Entry Ideas - newser.com
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo! Finance UK
Why ACADIA Pharmaceuticals Inc. stock is rated strong buyRisk Management & Weekly Setup with ROI Potential - newser.com
ACADIA Pharmaceuticals Inc. (ACAD) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
EBITDA per share of ACADIA Pharmaceuticals Inc. – DUS:DR6 - TradingView
Is ACADIA Pharmaceuticals Inc. reversing from oversold territoryJuly 2025 Action & Weekly High Potential Alerts - newser.com
What drives ACADIA Pharmaceuticals Inc stock priceStock Buyback Announcements & Fast Growing Trading Plans - earlytimes.in
Ranking ACADIA Pharmaceuticals Inc. among high performing stocks via toolsQuarterly Trade Report & Daily Market Momentum Tracking - newser.com
ACADIA Pharmaceuticals Surges 53% as New Product Launches Fuel Fresh Valuation Debate - Sahm
ACADIA Pharmaceuticals Advances Phase 3 Study for Lewy Body Dementia Psychosis Treatment - MSN
Why ACADIA Pharmaceuticals Inc. stock appeals to dividend seekersMarket Activity Summary & Safe Entry Point Alerts - newser.com
How ACADIA Pharmaceuticals Inc. stock performs after earningsJuly 2025 Weekly Recap & Community Supported Trade Ideas - newser.com
Emerald Mutual Fund Advisers Trust Sells 175,778 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
How sentiment analysis helps forecast ACADIA Pharmaceuticals Inc.2025 Valuation Update & Long-Term Growth Stock Strategies - newser.com
Is ACADIA Pharmaceuticals Inc. stock supported by strong fundamentalsTrend Reversal & Stepwise Swing Trade Plans - newser.com
Real time alert setup for ACADIA Pharmaceuticals Inc. performanceJuly 2025 Sector Moves & Consistent Profit Trade Alerts - newser.com
Acadia Pharma plots space to grow at Kilroy's big South San Francisco campus - The Business Journals
ACADIA Pharmaceuticals (ACAD): Exploring Valuation as Investor Interest Rises on Pipeline Momentum - Yahoo Finance
Emerald Advisers LLC Sells 223,547 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Advances Study on Carbetocin Nasal Spray for Prader-Willi Syndrome - MSN
ACADIA’s ACP-204 Study: A Promising Step for Alzheimer’s Disease Psychosis Treatment - MSN
12,050 Shares in ACADIA Pharmaceuticals Inc. $ACAD Bought by Yorktown Management & Research Co Inc - MarketBeat
ACADIA Pharmaceuticals (ACAD): Exploring Valuation After Strong Share Price Momentum and Pipeline Progress - Sahm
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):